CL2016001348A1 - Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others. - Google Patents
Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others.Info
- Publication number
- CL2016001348A1 CL2016001348A1 CL2016001348A CL2016001348A CL2016001348A1 CL 2016001348 A1 CL2016001348 A1 CL 2016001348A1 CL 2016001348 A CL2016001348 A CL 2016001348A CL 2016001348 A CL2016001348 A CL 2016001348A CL 2016001348 A1 CL2016001348 A1 CL 2016001348A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- triazol
- imidazol
- benzo
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FORMA CRISTALINA DEL COMPUESTO S)-(2-(6-CLORO-7-METIL-1H-BENZO[D]IMIDAZOL-2-IL)-2-METIL-PIRROLIDIN-1-IL)(5-METOXI-2-(2H-1,2,3-TRIAZOL-2-IL)FENIL)METANONA SUS SALES, ANTAGONISTA DEL RECEPTOR DE OREXINA; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO O PRECENCIPN DE NUN AENFERMEDAD O TRASTORNO SELECCIONADO DEL GRUPO ENTRE TRASTORNOS EL SUEÑO, TRASTORNOS DE ANSIEDAD, DE ADICCION DE HUMOR, DEL APETITO Y DISFUNCIONES COGNITIVAS.CRYSTAL FORM OF COMPOUND S) - (2- (6-CHLORINE-7-METHYL-1H-BENZO [D] IMIDAZOL-2-IL) -2-METHYL-PIRROLIDIN-1-IL) (5-METOXI-2- ( 2H-1,2,3-TRIAZOL-2-IL) PHENYL) METANONE ITS SALTS, OREXINE RECEIVER ANTAGONIST; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OR PREVENTION OF ANY DISEASE OR DISORDER SELECTED FROM THE GROUP BETWEEN SLEEP DISORDERS, ANXIETY DISORDERS, HUMOR ADDICTION, APPETITE AND COGNITIVE DYSFUNCTIONS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013060595 | 2013-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001348A1 true CL2016001348A1 (en) | 2016-11-25 |
Family
ID=52282787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001348A CL2016001348A1 (en) | 2013-12-03 | 2016-06-02 | Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others. |
Country Status (32)
Country | Link |
---|---|
US (2) | US9790208B2 (en) |
EP (1) | EP3077390B1 (en) |
JP (1) | JP6091716B2 (en) |
KR (1) | KR101839716B1 (en) |
CN (1) | CN105793258B (en) |
AU (1) | AU2014358743B2 (en) |
CA (1) | CA2929720C (en) |
CL (1) | CL2016001348A1 (en) |
CY (1) | CY1119687T1 (en) |
DK (1) | DK3077390T3 (en) |
EA (1) | EA030109B1 (en) |
ES (1) | ES2651508T3 (en) |
HK (1) | HK1225736B (en) |
HR (1) | HRP20171772T1 (en) |
HU (1) | HUE034656T2 (en) |
IL (1) | IL245922B (en) |
LT (1) | LT3077390T (en) |
MA (1) | MA39164B1 (en) |
MX (1) | MX362701B (en) |
MY (1) | MY176244A (en) |
NO (1) | NO3077390T3 (en) |
NZ (1) | NZ721493A (en) |
PH (1) | PH12016500989A1 (en) |
PL (1) | PL3077390T3 (en) |
PT (1) | PT3077390T (en) |
SA (1) | SA516371248B1 (en) |
SG (1) | SG11201604541WA (en) |
SI (1) | SI3077390T1 (en) |
TW (1) | TWI636982B (en) |
UA (1) | UA119151C2 (en) |
WO (1) | WO2015083071A1 (en) |
ZA (1) | ZA201604501B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104334544B (en) | 2012-06-04 | 2016-10-19 | 埃科特莱茵药品有限公司 | Benzimidazole proline derivative |
MX364208B (en) * | 2013-12-03 | 2019-04-16 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol -2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2- yl)phenyl)methanone and its use as orexin receptor antagonists. |
UA119151C2 (en) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
JP6421185B2 (en) | 2013-12-04 | 2018-11-07 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
IL270274B (en) | 2017-05-03 | 2022-08-01 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
KR20230004670A (en) | 2020-04-19 | 2023-01-06 | 이도르시아 파마슈티컬스 리미티드 | Medical Uses of Daridorexant |
WO2023160004A1 (en) * | 2022-02-25 | 2023-08-31 | 南京知和医药科技有限公司 | Fused-ring compound having analgesic activity, and preparation method therefor and use thereof |
CN117736193A (en) * | 2023-12-19 | 2024-03-22 | 南京知和医药科技有限公司 | Deuterated condensed ring compound and preparation method and application thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
CA2450922C (en) | 2000-06-16 | 2010-02-16 | Clive Leslie Branch | Piperidines for use as orexin receptor antagonists |
CA2425185A1 (en) | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
ATE286897T1 (en) | 2000-11-28 | 2005-01-15 | Smithkline Beecham Plc | MORPHOLINE DERIVATIVES AS ANTAGONISTS AT OREXIN RECEPTORS |
NZ528851A (en) | 2001-05-05 | 2006-03-31 | Smithkline Beecham P | N-aroyl cyclic amines |
WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
CZ20033437A3 (en) | 2001-06-28 | 2004-09-15 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives functioning as orexin receptor antagonists |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
US20060040937A1 (en) | 2002-09-18 | 2006-02-23 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
RU2378257C2 (en) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Substituted derivatives of 1, 2, 3, 4-tetrahydroisoquinoline |
US20090082394A1 (en) | 2006-03-15 | 2009-03-26 | Actelion Pharmaceuticals, Ltd. | Tetrahydroisoquinoline Derivatives to Enhance Memory Function |
WO2007135527A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
DE602007012910D1 (en) | 2006-08-15 | 2011-04-14 | Actelion Pharmaceuticals Ltd | AZETIDIN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS |
ATE481383T1 (en) | 2006-09-29 | 2010-10-15 | Actelion Pharmaceuticals Ltd | 3-AZA-BICYCLOÄ3.1.0ÜHEXANE DERIVATIVES |
PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
AR064561A1 (en) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM. |
WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
CL2008000836A1 (en) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others. |
DE602008002934D1 (en) | 2007-05-14 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 2-CYCLOPROPYLTHIAZOLDERIVATE |
EP2150115B1 (en) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
PL2164847T3 (en) | 2007-07-03 | 2012-02-29 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
BRPI0812981A2 (en) | 2007-07-03 | 2014-12-16 | Glaxo Group Ltd | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS |
CA2693817A1 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
EP2183246A2 (en) | 2007-07-27 | 2010-05-12 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo-[3.3.0]-octane derivatives |
CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
PE20091010A1 (en) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | TETRAHYDROQUINOLINE DERIVATIVES |
EP2247586B1 (en) | 2008-02-21 | 2012-04-25 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
US20110105491A1 (en) | 2008-07-07 | 2011-05-05 | Hamed Aissaoui | Thiazolidine compounds as orexin receptor antagonists |
WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
JP2012509911A (en) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | New compounds |
EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
WO2010060472A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
CN102300857A (en) | 2008-12-02 | 2011-12-28 | 葛兰素集团有限公司 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] Methyl}-2-heteroarylamine Derivatives And Uses Thereof |
AU2009324238A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
GB0823467D0 (en) * | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
MX2011011127A (en) | 2009-04-24 | 2011-11-18 | Glaxo Group Ltd | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists. |
TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
CA2815179A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
JP5987005B2 (en) | 2011-02-18 | 2016-09-06 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
US9150566B2 (en) | 2011-11-08 | 2015-10-06 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists |
PT2838900T (en) | 2012-04-17 | 2019-11-15 | Gilead Sciences Inc | Compounds and methods for antiviral treatment |
CN104334544B (en) * | 2012-06-04 | 2016-10-19 | 埃科特莱茵药品有限公司 | Benzimidazole proline derivative |
KR102151288B1 (en) * | 2012-10-10 | 2020-09-03 | 이도르시아 파마슈티컬스 리미티드 | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
KR20150130413A (en) | 2013-03-12 | 2015-11-23 | 액테리온 파마슈티칼 리미티드 | Azetidine amide derivatives as orexin receptor antagonists |
UA119151C2 (en) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
MX364208B (en) | 2013-12-03 | 2019-04-16 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol -2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2- yl)phenyl)methanone and its use as orexin receptor antagonists. |
JP6421185B2 (en) | 2013-12-04 | 2018-11-07 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
-
2014
- 2014-02-12 UA UAA201607115A patent/UA119151C2/en unknown
- 2014-12-02 MA MA39164A patent/MA39164B1/en unknown
- 2014-12-02 TW TW103141830A patent/TWI636982B/en active
- 2014-12-02 US US15/101,832 patent/US9790208B2/en active Active
- 2014-12-02 HU HUE14824108A patent/HUE034656T2/en unknown
- 2014-12-02 CN CN201480065749.2A patent/CN105793258B/en active Active
- 2014-12-02 SI SI201430453T patent/SI3077390T1/en unknown
- 2014-12-02 LT LTEP14824108.6T patent/LT3077390T/en unknown
- 2014-12-02 PL PL14824108T patent/PL3077390T3/en unknown
- 2014-12-02 MX MX2016007216A patent/MX362701B/en active IP Right Grant
- 2014-12-02 EA EA201600436A patent/EA030109B1/en not_active IP Right Cessation
- 2014-12-02 KR KR1020167017678A patent/KR101839716B1/en active IP Right Grant
- 2014-12-02 JP JP2016536106A patent/JP6091716B2/en active Active
- 2014-12-02 MY MYPI2016701995A patent/MY176244A/en unknown
- 2014-12-02 CA CA2929720A patent/CA2929720C/en active Active
- 2014-12-02 WO PCT/IB2014/066509 patent/WO2015083071A1/en active Application Filing
- 2014-12-02 ES ES14824108.6T patent/ES2651508T3/en active Active
- 2014-12-02 NO NO14824108A patent/NO3077390T3/no unknown
- 2014-12-02 AU AU2014358743A patent/AU2014358743B2/en active Active
- 2014-12-02 PT PT148241086T patent/PT3077390T/en unknown
- 2014-12-02 NZ NZ721493A patent/NZ721493A/en unknown
- 2014-12-02 SG SG11201604541WA patent/SG11201604541WA/en unknown
- 2014-12-02 EP EP14824108.6A patent/EP3077390B1/en active Active
- 2014-12-02 DK DK14824108.6T patent/DK3077390T3/en active
-
2016
- 2016-05-26 PH PH12016500989A patent/PH12016500989A1/en unknown
- 2016-05-30 IL IL24592216A patent/IL245922B/en active IP Right Grant
- 2016-06-01 SA SA516371248A patent/SA516371248B1/en unknown
- 2016-06-02 CL CL2016001348A patent/CL2016001348A1/en unknown
- 2016-07-01 ZA ZA2016/04501A patent/ZA201604501B/en unknown
- 2016-12-14 HK HK16114201A patent/HK1225736B/en unknown
-
2017
- 2017-09-12 US US15/702,281 patent/US10023560B2/en active Active
- 2017-11-16 HR HRP20171772TT patent/HRP20171772T1/en unknown
- 2017-12-12 CY CY20171101302T patent/CY1119687T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001348A1 (en) | Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others. | |
CY1119361T1 (en) | 3,4-Dihydroisoquinoline-2 (1H) -Material Compounds | |
CL2015002628A1 (en) | Heteroaryl compounds and their uses. | |
CU20160149A7 (en) | FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS AND ITS USE AS IRAK4 INHIBITORS | |
CL2014001793A1 (en) | Compounds derived from substituted 1,3,5-triazines and their salts, as inhibitors of mutant idh2; pharmaceutical composition that includes them; and its use for the treatment of cancer. | |
UY35675A (en) | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA | |
CO6501189A2 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
CL2014000659A1 (en) | Compounds derived from 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) picolinamide, orexin receptor antagonists; pharmaceutical composition; and its use for the prevention or treatment of a disease selected from the group consisting of anxiety, addiction, mood and appetite disorders. | |
CL2009000873A1 (en) | Compounds derived from cyclohepta [b] pyridine, antagonists of the cgrp receptor; pharmaceutical composition; and use for the treatment of migraine b. | |
CL2016001342A1 (en) | Crystalline forms hemihydrate and anhydrate of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- (2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising them; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others. | |
CL2016002169A1 (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders. | |
CL2008001658A1 (en) | Pharmaceutical composition comprising amorphous imatinib mesylate and a formulation principle that stabilizes the amorphous form; and its use to treat advanced and recently diagnosed chronic myeloid leukemia, chronic myelomonocytic leukemia, glioblastoma multiforme, among others. | |
CL2013003686A1 (en) | Ergoline-derived compounds, 5-ht1d receptor antagonist; useful for the treatment of migraine. | |
PA8795701A1 (en) | DERIVATIVES OF ISOQUINOLINILO AND ISOINDOLINILO AS ANTAGONISTS OF HISTAMINE-3 | |
CR11500A (en) | CYCLOPROPYLAMINE DERIVATIVES | |
PA8795601A1 (en) | DERIVATIVES OF AZACICLILISOQUINOLINONA AND ISOINDOLINONA AS ANTAGONISTS OF HISTAMINE-3 | |
CL2014002847A1 (en) | Triazolo derivative compounds, pde10 inhibitors; preparation procedure; use for the treatment and / or prophylaxis of psychotic disorders, schizophrenia, anxiety, drug addiction, parkinson's disease, among others. | |
CL2015003195A1 (en) | Purine derivatives as cb2 receptor agonists. | |
UY33722A (en) | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | |
CL2015001881A1 (en) | Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition. | |
ECSP088176A (en) | DERIVATIVES OF AZINIL-3-SULFONYLINDAZOL AS LIGANDS DE5-HYDROXYTHYRIPTAMINE-6 | |
CL2015003037A1 (en) | Triazine derivatives | |
ECSP088930A (en) | DERIVATIVES OF BENZOXAZOL AND BENZOTIAZOL AS LIGANDOS OF | |
UY34734A (en) | AN H3 RECEIVER ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE. | |
CL2012000102A1 (en) | Compounds derived from (phenyl / pyridine) -etinyl-imidazole, antagonists of the metabotropic glutamate receptors (mglur5); preparation procedure; and its use for the treatment and prevention of Alzheimer's, senile dementia, Parkinson's, among others. |